John Kilcoyne, JenaValve’s Chief Executive Officer said, "We are pleased to complete this financing led by new investor Bain Capital Life Sciences, a well-respected name in healthcare, as well as strong participation from our existing venture investors.
U.S. Patient Enrollment in Early Feasibility Study of Next-Generation TAVR System for the Treatment of Severe Aortic Stenosis and Severe Aortic Regurgitation Initiated
8/3/18: “It has been our goal since the early development of our next generation TAVR System to bring this novel technology into the United States,” said JenaValve Chief Executive Officer Victoria Carr-Brendel, PhD. “We are greatly encouraged to initiate enrollment at these prestigious centers under the direction of these physicians, and thank them for their efforts. We will continue to work tirelessly with our clinical partners to expand patient enrollment at new clinical sites in the United States.”
JenaValve Technology Continues CE Mark Study Treating Severe Aortic Stenosis with Next-Generation System; Patient Enrollment and Successful Implantations with the Everdur™ Pericardial Aortic Valve and Coronatix™ Delivery Catheter
4/10/18: Clinical evidence mounting in support of JenaValve Pericardial TAVR System with Everdur™ transcatheter valve and advanced Coronatix™ transfemoral delivery catheter.